期刊
BMC MEDICINE
卷 20, 期 1, 页码 -出版社
BMC
DOI: 10.1186/s12916-021-02206-y
关键词
Genetic marker; Structural variant; Amyotrophic lateral sclerosis; Clinical trials; Participant selection; Enrichment tool; Responder sub-population
This article discusses the role of recent discoveries of short structural variations (SSVs) in ALS and how these findings can be applied to future clinical trials. These discoveries help reduce participant heterogeneity and improve outcomes of ALS clinical trials.
There is considerable variability in disease progression for patients with amyotrophic lateral sclerosis (ALS) including the age of disease onset, site of disease onset, and survival time. There is growing evidence that short structural variations (SSVs) residing in frequently overlooked genomic regions can contribute to complex disease mechanisms and can explain, in part, the phenotypic variability in ALS patients. Here, we discuss SSVs recently characterized by our laboratory and how these discoveries integrate into the current literature on ALS, particularly in the context of application to future clinical trials. These markers may help to identify and differentiate patients for clinical trials that have a similar ALS disease mechanism(s), thereby reducing the impact of participant heterogeneity. As evidence accumulates for the genetic markers discovered in SQSTM1, SCAF4, and STMN2, we hope to improve the outcomes of future ALS clinical trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据